TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00410397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Pelvic balancing, myofascial release of the anterior pelvis.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Manipulation
Description: Neutral positional, gentle palpation
Study: NCT00772213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIGTS treatment
Description: treatment of multiple trauma patients in the MIGTS
Study: NCT03712189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeFlow
Description: The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
Study: NCT00615238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus continuous bouts
Description: Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus short bouts
Description: Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus moderate lifestyle activity
Description: Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
Study: NCT00995007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD6474 (Vandetanib)
Description: Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD6474 (Vandetanib)
Description: Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
Study: NCT01744353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 1
Description: Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 2/MTD
Description: Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 3
Description: Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Study: NCT02370680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: steady-state run-in prior to Durlaza treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: steady-state run-in prior to Durlaza treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durlaza™
Description: comparison of different numbers of capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durlaza™
Description: comparison of different numbers of capsules
Study: NCT02066051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL
Description: Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian Gland Expression
Description: After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
Study: NCT01170546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plate-loaded kneeling leg curl with internal rotation
Description: The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plate-loaded squat press
Description: The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plate-loaded kneeling leg curl
Description: An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
Study: NCT06473376

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthrocentesis
Description: TMJ arthrocentesis and arthroscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthrocentesis
Description: TMJ arthrocentesis and arthroscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthrocentesis
Description: TMJ arthrocentesis and arthroscopy
Study: NCT00959972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
Study: NCT00662350

Intervention type: DEVICE
Intervention: The Wallterm™ System
Description: The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
Study: NCT01788267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scan examination HR-pQCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scan examination HR-pQCT
Study: NCT01686360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Study: NCT00565383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Description: Combined spinal-epidural

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl (50mcg)
Description: Intravenous fentanyl
Study: NCT01831830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Veterans' In-home Program
Description: VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
Study: NCT04600479

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of the prevalence of HCV, HBV and HIV viral infections
Description: 1. Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~   In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~2. Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up.
Study: NCT03270332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: inhalation of 270μg albuterol through a spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: inhalation of 270μg albuterol through a spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inhalation of placebo through a spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inhalation of placebo through a spacer
Study: NCT00486876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextofisopam
Description: capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextofisopam
Description: capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextofisopam
Description: capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextofisopam
Description: capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
Study: NCT00980681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Each subject will receive one injection of Dotarem 0.2ml/kg

Intervention type: OTHER
Group type: OTHER
Intervention: Time of Flight
Description: Each subject will undergo a TOF MRA
Study: NCT01615380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT+ Contact
Description: In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+ Exercise
Description: Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
Study: NCT03951779

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise cardiac magnetic resonance imaging
Description: Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
Study: NCT02679339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-2022 (lidocaine gel, 40%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00390611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin
Study: NCT04435379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
Study: NCT04190433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Given PO
Study: NCT01317225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 α hydroxyprogesterone caproate
Description: 250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
Study: NCT03675776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration).
Study: NCT02031939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)
Description: All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard chemoradiotherapy
Description: All rectal patients in this group will receive standard radiotherapy and surgical resection.
Study: NCT04567667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kinevac®
Description: Specified dose on specified days
Study: NCT02537938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGP 555
Study: NCT01494350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396 topical cream
Description: WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
Study: NCT02608879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Mucosa Deterging and Periodontal Debridement (OMDP)
Description: OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Oral Hygiene Instructions
Description: Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental scaling, ultrasonic
Description: An ultrasonic dental scaler will be used to clean the teeth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
Study: NCT00717054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine transdermal applied to skin behind the ear one hour prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
Study: NCT03444727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Pre-treatment
Description: Topical application of ice prior to local anesthetic injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room Temperature Water Pre-treatment
Description: Topical application of room-temperature water prior to local anesthetic injection.
Study: NCT03588299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2599023 (DTX201)
Description: Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
Study: NCT01947452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment
Description: Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment
Description: Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-Emotional Learning
Description: Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
Study: NCT01764048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fix protocol
Description: Please see arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medications following demand protocol
Description: Please see arm description
Study: NCT03689647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm Swing Driven Assistive Apparatus
Description: The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
Study: NCT00691886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine hydrochloride
Description: Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
Study: NCT02870413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telelactation services
Description: Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
Study: NCT03075423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Description: Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard of Care therapy is administered according to the physician´s decision.
Study: NCT04506307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study: NCT03600623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine nab-Paclitaxel
Description: SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).